Template talk:Management of pulmonary arterial hypertension

Pharmacology Template‑class

	This template is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Template	This template does not require a rating on Wikipedia's content assessment scale.

Medicine Template‑class

	Medicine portal This template is within the scope of WikiProject Medicine. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Template	This template does not require a rating on Wikipedia's content assessment scale.

Hello, I was wondering whether medicines that are currently undergoing clinical trials for pulmonary hypertension, such as ambrisentan and tadalafil, should be added to this template. --Kyoko 19:14, 6 April 2007 (UTC)[reply]

Hi Kyoko. I thought of doing so, but couldn't come to a decision; if you check the code, you'll see ambrisentan is in there, just commented out. {{Chemotherapeutic agents}} contains drugs such as vandetanib which are still in trials; perhaps this template could follow that example? Fvasconcellos 19:18, 6 April 2007 (UTC)[reply]

I still don't know. I guess it would be fine. I'll be bold and edit the template. --Kyoko 20:57, 6 April 2007 (UTC)[reply]

I've added in hidden comments the group statins and the drug simvastatin, which has been tried in both humans and test rats. I'm not aware of any current clinical trial of simvastatin in the US, but I think there's one in England. I didn't want to be too bold and just add it in plain view. --Kyoko 04:08, 23 April 2007 (UTC)[reply]

Nice. I wasn't aware of the role of statins, but a quick PubMed search suggests encouraging results in humans and animal models. We should probably wait until more advanced trials are underway before making it visible though—e.g., ambrisentan is in Phase III and already has marketing validation in the EU, simvastatin is still in Phase I–II. Fvasconcellos (t·c) 15:48, 23 April 2007 (UTC)[reply]

P.S.: here's the link to the English trial. Fvasconcellos (t·c) 15:49, 23 April 2007 (UTC)[reply]

use of template on "Adjunctive therapy" articles?[edit]

I've been wondering whether this template should also be placed on the articles mentioned under "Adjunctive therapy". It's on the CCB and diuretics main articles, but not specifically on nifedipine and hydrochlorothiazide. It seems slightly spammy to me to put it on every single drug in the categories, and that wouldn't accurate either. --Kyoko 15:50, 21 April 2007 (UTC)[reply]

Hmm. Honestly, my first thought is to keep it only on the main class article... Do you think it would be better placed in specific drug articles? I'd prefer to keep the adjunctive therapy section of the template generalized. Fvasconcellos (t·c) 20:00, 21 April 2007 (UTC)[reply]

No, I don't think it would be better placed in the specific drug articles, but I wanted a second opinion. I especially wouldn't want the "Adjunctive therapy" section of the template to get too large. Thanks. --Kyoko 21:18, 21 April 2007 (UTC)[reply]